Lisata Therapeutics (LSTA) Projected to Announce Quarterly Earnings on Thursday

Lisata Therapeutics (NASDAQ:LSTA) is expected to post its results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($1.1250) per share and revenue of $0.66 million for the quarter.

Lisata Therapeutics (NASDAQ:LSTA) last released its earnings results on Thursday, August 6th. The company reported ($0.32) earnings per share (EPS) for the quarter.

Lisata Therapeutics Trading Up 3.9%

Shares of LSTA opened at $1.06 on Thursday. The business’s 50 day moving average is $1.40 and its 200 day moving average is $2.99. The company has a market capitalization of $11.45 million, a PE ratio of -0.65 and a beta of 0.94. Lisata Therapeutics has a 12-month low of $0.96 and a 12-month high of $5.07.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Lisata Therapeutics presently has an average rating of “Reduce”.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors.

Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively.